Cancer vaccination drives nanog-dependent evolution of tumor cells toward an immune-resistant and stem-like phenotype

Cancer Research

Volumn 72, Issue 7, 2012, Pages 1717-1727

  Noh, Kyung Hee ^a   Lee, Young Ho ^a   Jeon, Ju Hong ^b   Kang, Tae Heung ^c   Mao, Chih Ping ^c   Wu, T C ^c   Kim, Tae Woo ^a  

^a Korea University College of Medicine   (South Korea)

^b Seoul National University   (South Korea)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR 1; GRANZYME B; TRANSCRIPTION FACTOR NANOG;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER IMMUNIZATION; CANCER INHIBITION; CANCER STEM CELL; CARCINOGENICITY; CD8+ T LYMPHOCYTE; CELL CYCLE S PHASE; CONTROLLED STUDY; CYTOLYSIS; CYTOTOXIC T LYMPHOCYTE; FEMALE; IMMUNE RESPONSE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN TARGETING; TUMOR CELL; TUMOR ESCAPE; TUMOR GROWTH; TUMOR IMMUNITY;

ANIMALS; CANCER VACCINES; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; IMMUNE TOLERANCE; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; PHENOTYPE; T-LYMPHOCYTES, CYTOTOXIC; VACCINATION;

EID: 84859417830     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-11-3758     Document Type: Article

References (38)

1. Stauss HJ. Immunotherapy with CTLs restricted by nonself MHC. Immunology Today 1999;20:180-3.
2. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009;373:673-83.
3. Kraemer M, Hauser S, Schmidt-Wolf IG. Long-term survival of patients with metastatic renal cell carcinoma treated with pulsed dendritic cells. Anticancer Res 2010;30:2081-6.
4. Dillman RO, Selvan SR, Schiltz PM, McClay EF, Barth NM, DePriest C, et al. Phase II trial of dendritic cells loaded with antigens from self-renewing, proliferating autologous tumor cells as patient-specific antitumor vaccines in patients with metastatic melanoma: final report. Cancer Biother Radiopharm 2009;24:311-9.
5. Lesterhuis WJ, Haanen JB, Punt CJ. Cancer immunotherapy-revisited. Nat Rev Drug Dis 2011;10:591-600.
6. Kruger C, Greten TF, Korangy F. Immune based therapies in cancer. Histol Histopathol 2007;22:687-96. (Pubitemid 46647280)
7. Aptsiauri N, Carretero R, Garcia-Lora A, Real LM, Cabrera T, Garrido F. Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. Cancer Immunol Immunother 2008;57:1727-33.
8. Curiel TJ, Coukos G, Zou L, Alvarez X, Cheng P, Mottram P, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-9. (Pubitemid 39273735)
9. Gajewski TF. Identifying and overcoming immune resistance mechanisms in the melanoma tumor microenvironment. Clin Cancer Res 2006;12:2326s-30s.
10. Schatton T, Frank MH. Antitumor immunity and cancer stem cells. Ann N Y Acad Sci 2009;1176:154-69.
11. Wilczynski JR, Duechler M. How do tumors actively escape from host immunosurveillance? Arch Immunol Ther Ex 2010;58:435-48.
12. Han HD, Mangala LS, Lee JW, Shahzad MM, Kim HS, Shen D, et al. Targeted gene silencing using RGD-labeled chitosan nanoparticles. Clin Cancer Res 2010;16:3910-22.
13. Lin KY, Guarnieri FG, Staveley-O'Carroll KF, Levitsky HI, August JT, Pardoll DM, et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. Cancer Res 1996;56:21-6. (Pubitemid 26010379)
14. Kang TH, Kim KW, Bae HC, Seong SY, Kim TW. Enhancement of DNA vaccine potency by antigen linkage to IFN-gamma-inducible protein-10. Int J Cancer 2011;128:702-14.
15. Noh KH, Kang TH, Kim JH, Pai SI, Lin KY, Hung CF, et al. Activation of Akt as a mechanism for tumor immune evasion. Mol Ther 2009;17:439-47.
16. Chen CH, Wang TL, Hung CF, Yang Y, Young RA, Pardoll DM, et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. Cancer Res 2000;60:1035-42. (Pubitemid 30129542)
17. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nature Immunology 2002;3:991-8. (Pubitemid 35363648)
18. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011;331:1565-70.
19. Wu TC. The role of vascular cell adhesion molecule-1 in tumor immune evasion. Cancer Res 2007;67:6003-6.
20. Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A 1995;92:11671-5. (Pubitemid 26014175)
21. Chen CH, Wang TL, Ji H, Hung CF, Pardoll DM, Cheng WF, et al. Recombinant DNA vaccines protect against tumors that are resistant to recombinant vaccinia vaccines containing the same gene. Gene Therapy 2001;8:128-38. (Pubitemid 32162426)
22. Frank NY, Schatton T, Frank MH. The therapeutic promise of the cancer stem cell concept. J Clin Invest 2010;120:41-50.
23. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer 2005;5:275-84. (Pubitemid 40488633)
24. Du Z, Qin R, Wei C, Wang M, Shi C, Tian R, et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2011;56:741-50.
25. Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE. Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 2008;3:e3077.
26. Diehn M, Clarke MF. Cancer stem cells and radiotherapy: new insights into tumor radioresistance. J Natl Cancer Inst 2006;98:1755-7. (Pubitemid 46017927)
27. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008;8:755-68.
28. Zhou BB, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov 2009;8:806-23.
29. Singec I, Knoth R, Meyer RP, Maciaczyk J, Volk B, Nikkhah G, et al. Defining the actual sensitivity and specificity of the neurosphere assay in stem cell biology. Nat Methods 2006;3:801-6. (Pubitemid 44445827)
30. Gu W, Yeo E, McMillan N, Yu C. Silencing oncogene expression in cervical cancer stem-like cells inhibits their cell growth and self-renewal ability. Cancer Gene Ther 2011;18:897-905.
31. Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M, et al. CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 2010;120:485-97.
32. Zielske SP, Spalding AC, Wicha MS, Lawrence TS. Ablation of breast cancer stem cells with radiation. Transl Oncol 2011;4:227-33.
33. Wu A, Oh S, Wiesner SM, Ericson K, Chen L, Hall WA, et al. Persistence of CD133+ cells in human and mouse glioma cell lines: detailed characterization of GL261 glioma cells with cancer stem cell-like properties. Stem Cells Dev 2008;17:173-84. (Pubitemid 351271617)
34. Wu Y, Wu PY. CD133 as a marker for cancer stem cells: progresses and concerns. Stem Cells Deve 2009;18:1127-34.
35. Yamaguchi S, Kurimoto K, Yabuta Y, Sasaki H, Nakatsuji N, et al. Conditional knockdown of Nanog induces apoptotic cell death in mouse migrating primordial germ cells. Development 2009;136:4011-20.
36. Siu MK, Wong ES, Chan HY, Ngan HY, Chan KY, Cheung AN. Overexpression of NANOG in gestational trophoblastic diseases: effect on apoptosis, cell invasion, and clinical outcome. Am J Pathol 2008;173:1165-72.
37. Ma T, Wang Z, Guo Y, Pei D. The C-terminal pentapeptide of Nanog tryptophan repeat domain interacts with Nac1 and regulates stem cell proliferation but not pluripotency. J Biol Chem 2009;284:16071-81.
38. Kang TH, Noh KH, Kim JH, Bae HC, Lin KY, Monie A, et al. Ectopic expression of X-linked lymphocyte-regulated protein pM1 renders tumor cells resistant to antitumor immunity. Cancer Research 2010;70:3062-70.